---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-023462"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2024-02-05T23:59:59+00:00"
generated_at: "2026-06-06T09:11:09.213834+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Spyre appoints Mark McKenna as director; CEO severance amended

## Summary
- Alison Lawton resigned from Board effective Feb 1, 2024; no disagreement cited.
- Mark McKenna appointed Class I director; former CEO of Prometheus Biosciences (acquired by Merck).
- CEO Cameron Turtle's severance increased by 0.5x target bonus in change-in-control event.
- McKenna granted option for 40,000 shares under equity plan; consulting agreement grants 477,000 options.
- Board adopted amended bylaws, new code of conduct, and indemnification agreements for directors/officers.

## SEC filing metadata
- accession: 0001193125-24-023462
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2024-02-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 5.02, 5.03, 5.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000119312524023462/0001193125-24-023462-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000119312524023462/d732838d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-023462
- JSON: https://secwatch.observer/filing/0001193125-24-023462.json
- Plain text: https://secwatch.observer/filing/0001193125-24-023462.txt

## Key facts
- Executive change
  Alison Lawton resigned as Director at Spyre Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On February 1, 2024, Alison Lawton resigned from the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312524023462/0001193125-24-023462-index.htm
- Executive change
  Mark McKenna was appointed as Class I director at Spyre Therapeutics, Inc..
  - Action: appointed
  - Role: Class I director
  source text: On February 1, 2024, the Board appointed Mark McKenna as a Class I director to fill the vacancy resulting from Ms. Lawton’s resignation, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312524023462/0001193125-24-023462-index.htm
- Governance Changes
  Spyre Therapeutics, Inc.: Board amended and restated bylaws to revise voting standards, update stockholder proposal and director nomination requirements, opt out of DGCL Section 116, and update indemnification and other provisions (effective 2024-02-01).
  - Change: bylaw amendment
  - Effective: 2024-02-01
  source text: On February 1, 2024, the Board adopted an amendment and restatement of the Company’s Amended and Restated Bylaws as previously adopted by the Aeglea board of directors (as amended and restated, the “Amended and Restated Bylaws”), effective as of such date, in order to, among other things: • revise the voting standards for matters submitted to a vote of stockholders other than for the election of directors to be the affirmative vote of the holders of at least a majority of the voting power of the Company’s stock present in person or represented by proxy and entitled to vote on the matter, except as otherwise required by the Company’s Certificate of Incorporation, the Amended and Restated Bylaws, or any law, rule or regulation; • update the procedural and disclosure requirements for director nominations made and business proposals submitted by stockholders (other than proposals submitted pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended); • opt out of Section 1
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312524023462/0001193125-24-023462-index.htm
- Governance Changes
  Spyre Therapeutics, Inc.: Board adopted a new Code of Business Conduct and Ethics, superseding the prior code, with updated policies on compliance, conflicts of interest, whistleblower procedures, and other matters (effective 2024-02-01).
  - Change: code of ethics
  - Effective: 2024-02-01
  source text: On February 1, 2024, the Board adopted a new Code of Business Conduct and Ethics of the Company (the “Code of Conduct”), effective as of such date. The Code of Conduct supersedes the Company’s existing Code of Conduct and Ethics as previously adopted by the Aeglea board of directors (the “Existing Code of Conduct”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312524023462/0001193125-24-023462-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.